Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.4169
-0.0275-6.19%
Post-market: 0.4100-0.0069-1.66%19:52 EDT
Volume:545.82K
Turnover:235.83K
Market Cap:5.69M
PE:-0.11
High:0.4500
Open:0.4400
Low:0.4101
Close:0.4444
52wk High:14.80
52wk Low:0.4101
Shares:13.65M
Float Shares:12.33M
Volume Ratio:0.80
T/O Rate:4.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.18
PE(LYR):-0.10

Loading ...

VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay on Sysmex platform

Reuters
·
Jun 17

VolitionRX Announces Collaboration With Sysmex

THOMSON REUTERS
·
Jun 17

VolitionRx prices public offering to raise USD 4.6 million upfront

Reuters
·
Jun 10

VolitionRX Announces Pricing of $4.6 Million Public Offering

THOMSON REUTERS
·
Jun 08

VolitionRx files patent covering Nu.Q technology for Ebola triage

TIPRANKS
·
Jun 03

VolitionRx files patent application for Nu.Q NETs Ebola triage test

Reuters
·
Jun 03

VolitionRX - Seeks Partners for Field Trials and Deployment of Lft Prototypes in Outbreak Zones

THOMSON REUTERS
·
Jun 03

VolitionRX Files New Patent Protecting Its Nu.q® Nets Test for Ebola Triage and Treatment Monitoring

THOMSON REUTERS
·
Jun 03

VolitionRx posts corporate deck outlining Nu.Q licensing strategy across cancer, sepsis and veterinary testing

Reuters
·
May 28

VolitionRx posts $1 million Q1 revenue, up 300% year over year

Reuters
·
May 27

VolitionRx submits peer-reviewed study of Nu.Q Vet feline lymphoma blood test, eyes $5 million milestone

Reuters
·
May 27

VolitionRx waives Lind note covenant breach, triggers 10% step-up charge

Reuters
·
May 23

VolitionRX Earnings Call Balances Breakthroughs and Risks

TIPRANKS
·
May 20

VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk

TIPRANKS
·
May 16

VolitionRx director Mickie Henshall steps down, won’t seek re-election

Reuters
·
May 16

VolitionRx publishes corporate deck outlining Nu.Q licensing strategy in cancer, sepsis diagnostics

Reuters
·
May 15

BRIEF-VolitionRX Limited Announces First Quarter 2026 Financial Results

Reuters
·
May 15

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

Benzinga Earnings
·
May 15

VolitionRX Q1 FY26 net loss widens 22% to $6.7 million; revenue more than doubles to $1 million

Reuters
·
May 15

VolitionRx schedules first-quarter earnings conference call and business update

Reuters
·
May 11